{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310611","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.355344+00:00","generated_at":"2026-05-16T14:01:08.772720+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M","bullets":["Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.","Acquisition adds brelovitug, a Phase 3 monoclonal antibody for chronic hepatitis D (HDV) with Breakthrough Therapy and PRIME designations.","Mirum also raised $200M in a PIPE from investors including Morgan Stanley, Leerink, Cantor, Raymond James, and Citizens JMP.","Top-line Phase 3 data for brelovitug expected in second half of 2026; BLA submission anticipated in first half of 2027.","Transaction expected to close in Q1 2026, subject to HSR clearance, stockholder approval, and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310611","json":"https://secwatch.observer/filing/0001193125-25-310611.json","markdown":"https://secwatch.observer/filing/0001193125-25-310611.md","text":"https://secwatch.observer/filing/0001193125-25-310611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/0001193125-25-310611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/d46722d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T14:01:08.772720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}